Details

Autor(en) / Beteiligte

• Rodrigues, Tamara S
• de Sá, Keyla S G
• Ishimoto, Adriene Y
• Becerra, Amanda
• Oliveira, Samuel
• Almeida, Leticia
• Gonçalves, Augusto V
• Perucello, Debora B
• Andrade, Warrison A
• Castro, Ricardo
• Veras, Flavio P
• Toller-Kawahisa, Juliana E
• Nascimento, Daniele C
• de Lima, Mikhael H F
• Silva, Camila M S
• Caetite, Diego B
• Martins, Ronaldo B
• Castro, Italo A
• Pontelli, Marjorie C
• de Barros, Fabio C
• do Amaral, Natália B
• Giannini, Marcela C
• Bonjorno, Letícia P
• Lopes, Maria Isabel F
• Santana, Rodrigo C
• Vilar, Fernando C
• Auxiliadora-Martins, Maria
• Luppino-Assad, Rodrigo
• de Almeida, Sergio C L
• de Oliveira, Fabiola R
• Batah, Sabrina S
• Siyuan, Li
• Benatti, Maira N
• Cunha, Thiago M
• Alves-Filho, José C
• Cunha, Fernando Q
• Cunha, Larissa D
• Frantz, Fabiani G
• Kohlsdorf, Tiana
• Fabro, Alexandre T
• Arruda, Eurico
• de Oliveira, Renê D R
• Louzada-Junior, Paulo
• Zamboni, Dario S

Titel

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

Ist Teil von

• The Journal of experimental medicine, 2021-03, Vol.218 (3)

Ort / Verlag

United States: Rockefeller University Press

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Severe cases of COVID-19 are characterized by a strong inflammatory process that may ultimately lead to organ failure and patient death. The NLRP3 inflammasome is a molecular platform that promotes inflammation via cleavage and activation of key inflammatory molecules including active caspase-1 (Casp1p20), IL-1β, and IL-18. Although participation of the inflammasome in COVID-19 has been highly speculated, the inflammasome activation and participation in the outcome of the disease are unknown. Here we demonstrate that the NLRP3 inflammasome is activated in response to SARS-CoV-2 infection and is active in COVID-19 patients. Studying moderate and severe COVID-19 patients, we found active NLRP3 inflammasome in PBMCs and tissues of postmortem patients upon autopsy. Inflammasome-derived products such as Casp1p20 and IL-18 in the sera correlated with the markers of COVID-19 severity, including IL-6 and LDH. Moreover, higher levels of IL-18 and Casp1p20 are associated with disease severity and poor clinical outcome. Our results suggest that inflammasomes participate in the pathophysiology of the disease, indicating that these platforms might be a marker of disease severity and a potential therapeutic target for COVID-19.